First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Fenlai Tan(Betta Pharmaceuticals (China)), Helong Zhang(Shanghai International Studies University), Gongyan Chen(Harbin Medical University), Wěi Li(Shougang (China)), Chen Yao(Peking University), Ma Yong(Henan Cancer Hospital), Xinling Ren(Xijing Hospital), Song Xia(Shanxi Provincial Cancer Hospital), Shucai Zhang(Northeastern University), Yong Song(Nanjing General Hospital of Nanjing Military Command), Ning Wu(Regeneron (United States)), Ping Yu(Sichuan Cancer Hospital), Lieming Ding(Betta Pharmaceuticals (China)), J. Feng(Hangzhou First People's Hospital), Cuimin Ding(Hebei Medical University), Yunpeng Liu(Shenyang Institute of Automation), Xiaohong Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Lin Wang(Shanxi Academy of Medical Sciences), Baohui Han(Shanghai Jiao Tong University)
Cited by 14
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k